Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind …
CL Leonardi, AB Kimball, KA Papp, N Yeilding… - The Lancet, 2008 - thelancet.com
Background Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis.
We assessed ustekinumab, a human monoclonal antibody directed against these cytokines…
We assessed ustekinumab, a human monoclonal antibody directed against these cytokines…
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind …
KA Papp, RG Langley, M Lebwohl, GG Krueger… - The Lancet, 2008 - thelancet.com
Background Ustekinumab, a human monoclonal antibody against interleukins 12 and 23,
has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of …
has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of …
[HTML][HTML] Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis
KA Papp, C Leonardi, A Menter… - … England Journal of …, 2012 - Mass Medical Soc
Background In this phase 2, randomized, double-blind, placebo-controlled, dose-ranging
study, we assessed the efficacy and safety of brodalumab (AMG 827), a human anti–interleukin…
study, we assessed the efficacy and safety of brodalumab (AMG 827), a human anti–interleukin…
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year …
…, J Weisman, D Pariser, EL Simpson, KA Papp… - The Lancet, 2017 - thelancet.com
Background Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling
of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic …
of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic …
[HTML][HTML] Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis
KB Gordon, A Blauvelt, KA Papp… - … England Journal of …, 2016 - Mass Medical Soc
Background Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks
of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to …
of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to …
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp, S Tyring, M Lahfa, J Prinz… - British Journal of …, 2005 - academic.oup.com
Background In previous studies, etanercept significantly improved plaque psoriasis and was
well tolerated. Objectives To examine further the efficacy and safety of etanercept and to …
well tolerated. Objectives To examine further the efficacy and safety of etanercept and to …
[HTML][HTML] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with …
Background Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating
moderate to severe psoriasis in a phase II trial. Objectives We sought to compare efficacy …
moderate to severe psoriasis in a phase II trial. Objectives We sought to compare efficacy …
[HTML][HTML] Two phase 3 trials of adalimumab for hidradenitis suppurativa
…, DA Williams, AB Gottlieb, KA Papp… - … England Journal of …, 2016 - Mass Medical Soc
Background Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with
few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor …
few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor …
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled …
Background Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We …
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We …
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
PJ Mease, DD Gladman, KA Papp, MM Khraishi… - Journal of the American …, 2013 - Elsevier
… Papp MD, PhD c , Majed M. Khraishi MD d , Diamant Thaçi MD e , Frank Behrens MD e ,
Robert Northington PhD f , Joanne Fuiman MS f , … Dr Papp has no conflicts of interest to declare. …
Robert Northington PhD f , Joanne Fuiman MS f , … Dr Papp has no conflicts of interest to declare. …